Construction of a reporter system for fine assessment of the p53 activity in cultured cells

Molekulyarnaya Biologiya

Volumn 37, Issue 6, 2003, Pages 1007-1018

  Strunina, S M ^a   Ivanov, A V ^a   Chumakov, P M ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; PROTEIN P53; GREEN FLUORESCENT PROTEIN; PHOTOPROTEIN;

ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE CONSTRUCT; GENE EXPRESSION; GENE INDUCTION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REPORTER GENE; RETROVIRUS; TRANSCRIPTION INITIATION; GENETICS; PHYSIOLOGY; TUMOR CELL LINE;

BETA-GALACTOSIDASE; CELL LINE, TUMOR; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; PROMOTER REGIONS (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 2142815400     PISSN: 00268984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Baker S.J., Preisinger A.C., Jessup J.M., Paraskeva C., Markowitz S., Willson J.K., Hamilton S., Vogelstein B. 1990. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50, 7717-7722.
2. Soussi T. 2000. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. N.Y. Acad. Sci. 910, 121-137.
3. Thomas M., Pim D., Banks L. 1999. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 18, 7690-7700.
4. Momand J., Jung D., Wilczynski S., Niland J. 1998. The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459.
5. Haupt Y., Maya R., Kazaz A., Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature. 387, 296-299.
6. Sherr C.J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984-2991.
7. Lin J., Zhu M.H. 2003. [Interactive Pathway of ARF-mdm2-p53]. Ai Zheng. 22, 328-330.
8. Tao W., Levine A.J. 1999. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA. 96, 6937-6941.
9. Moll U.M., Ostermeyer A.G., Haladay R., Winkfield B., Frazier M., Zambetti G. 1996. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16, 1126-1137.
10. Caspari T. 2000. How to activate p53. Curr. Biol. 10, R315-317.
11. Chiarugi V., Cinelli M., Magnelli L. 1998. Acetylation and phosphorylation of the carboxy-terminal domain of p53: regulative significance. Oncol. Res. 10, 55-57.
12. Lin A.W., Lowe S.W. 2001. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. USA. 98, 5025-5030.
13. Agarwal M.L., Ramana C.V., Hamilton M., Taylor W.R., DePrimo S.E., Bean L.J., Agarwal A., Agarwal M.K., Wolfman A., Stark G.R. 2001. Regulation of p53 expression by the RAS-MAP kinase pathway. Oncogene. 20, 2527-2536.
14. Lakin N.D., Jackson S.P. 1999. Regulation of p53 in response to DNA damage. Oncogene. 18, 7644-7655.
15. Tishler R.B., Lamppu D.M., Park S., Price B.D. 1995. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res. 55, 6021-6025.
16. Rubtsova S.N., Kondratov R.V., Kopnin P.B., Chumakov P.M., Kopnin B.P., Vasiliev J.M. 1998. Disruption of actin microfilaments by cytochalasin D leads to activation of p53. FEBS Lett. 430, 353-357.
17. Di Leonardo A., Khan S.H., Linke S.P., Greco V., Seidita G., Wahl G.M. 1997. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57, 1013-1019.
18. Chernova O.B., Chernov M.V., Agarwal M.L., Taylor W.R., Stark G.R. 1995. The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Trends Biochem. Sci. 20, 431-434.
19. Sandau K., Pfeilschifter J., Brune B. 1998. Nitrosative and oxidative stress induced heme oxygenase-1 accumulation in rat mesangial cells. Eur. J. Pharmacol. 342, 77-84.
20. Ohnishi T., Wang X., Ohnishi K., Matsumoto H., Takahashi A. 1996. p53-dependent induction of WAF1 by heat treatment in human glioblastoma cells. J. Biol. Chem. 271, 14510-14513.
21. Lowe S.W. 1999. Activation of p53 by oncogenes. Endocr. Relat. Cancer. 6, 45-48.
22. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. 1992. Definition of a consensus binding site for p53. Nature Genet. 1, 45-49.
23. Hoh J., Jin S., Parrado T., Edington J., Levine A.J., Ott J. 2002. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. USA. 99, 8467-8472.
24. Zhao R., Gish K., Murphy M., Yin Y., Notterman D., Hoffman W.H., Tom E., Mack D.H., Levine A.J. 2000. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14, 981-993.
25. Pietenpol J.A., Tokino T., Thiagalingam S., El-Deiry W.S., Kinzler K. W., Vogelstein B. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA. 91, 1998-2002.
26. Park D.J., Chumakov A.M., Miller C.W., Pham E.Y., Koeffler H.P. 1996. p53 transactivation through various p53-responsive elements. Mol. Carcinog. 16, 101-108.
27. Komarova E.A., Chernov M.V., Franks R., Wang K., Armin G., Zelnick C.R., Chin D.M., Bacus S.S., Stark G.R., Gudkov A.V. 1997. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16, 1391-1400.
28. Chen J.Y., Funk W.D., Wright W.E., Shay J.W., Minna J.D. 1993. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene. 8, 2159-2166.
29. Zhang W.W., Labrecque S., Azoulay E., Dudley R., Matlashewski G. 2001. Development of a p53 responsive GFP reporter, identification of live cells with p53 activity. J. Biotechnol. 84, 79-86.
30. Renzing J., Lane D.P. 1995. p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene. 10, 1865-1868.
31. Funk W.D., Pak D.T., Karas R.H., Wright W.E., Shay J.W. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866-2871.
32. Brattain M.G., Fine W.D., Khaled P.M., Thompson J., Brattain D.E. 1981. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 41, 1751-1756.
33. Lieber M., Smith B., Szakal A., Nelson-Rees W., Todaro G. (1976). A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int. J. Cancer, 17, 62-70.
34. Kritchevsky D., Howard B.V. 1966. The lipids of human diploid cell strain WI-38. Ann. Med. Exp. Biol. Fenn. 44, 343-347.
35. Rasheed S., Nelson-Rees W.A., Toth E.M., Arnstein P., Gardner M.B. 1974. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 33, 1027-1033.
36. Ponten J., Saksela E. 1967. Two established in vitro cell lines from human mesenchymal tumours. Int. J. Cancer. 2, 434-447.
37. Grignani F., Kinsella T., Mencarelli A., Valtieri M., Riganelli D., Lanfrancone L., Peschle C., Nolan G.P., Pelicci P.G. 1998. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 58, 14-19.
38. Moll U.M., Riou G., Levine A.J. 1992. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA. 89, 7262-7266.
39. Yu S.F., von Ruden T., Kantoff P.W., Garber C., Seiberg M., Ruther U., Anderson W.F., Wagner E.F., Gilboa E. 1986. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA. 83, 3194-3198.
40. Gossen M., Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA. 89, 5547-5551.
41. el-Deiry W.S. 1998. p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol. 227, 121-137.
42. O'Connell M.J., Moertel C.G., Rubin J., Hahn R.G., Kvols L.K., Schutt A.J. 1984. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma. J. Clin. Oncol. 2, 1133-1138.
43. Violette S., Poulain L., Dussaulx E., Pepin D., Faussat A.M., Chambaz J., Lacorte J.M., Staedel C., Lesuffleur T. 2002. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int. J. Cancer. 98, 498-504.
44. Li W.W., Takahashi N., Jhanwar S., Cordon-Cardo C., Elisseyeff Y., Jimeno J., Faircloth G., Bertino J.R. 2001. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin. Cancer Res. 7, 2908-2911.
45. Jaiswal A.S., Narayan S. 2002. SN2 DNA-alkylating agent-induced phosphorylation of p53 and activation of p21 gene expression. Mutat. Res. 500, 17-30.
46. Park Y.B., Park M.J., Kimura K., Shimizu K., Lee S.H., Yokota J. 2002. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet. Cytogenet. 133, 105-111.
47. Wang L.G., Liu X.M., Kreis W., Budman D.R. 1999. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 44, 355-361.
48. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. 1999. Pharmacological rescue of mutant p53 conformation and function. Science. 286, 2507-2510.
49. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med. 8, 282-288.